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The introduction of lamivudine (LMV) for the treatment of chronic hepatitis B infection has been an important advance in the
management of this disease. However, the long-term efficacy of LMV may become limited by the emergence of antiviral-resistant
hepatitis B virus (HBV) mutants. The two most common LMV-resistant mutants produce changes in the viral polymerase protein
(rt) of rtM204I and rtL180M/M204V (previously rtM550I and rtL526M/M550V). A number of studies have demonstrated that these
HBV mutants appear to be replication impaired, both in vitro and in vivo. The detection and selection of compensatory mutations
in the polymerase protein that restore the replication phenotype of these HBV mutants have been poorly described to date. The
effects of mutations in the fingers subdomain of the viral polymerase protein arising as a consequence of vaccine and hepatitis
B immune globulin (HBIg) selected changes in the overlapping envelope gene (S), and a determinant of the hepatitis Bs antigen
(HBsAg) were analyzed in vitro. The LMV-resistant HBVmutants rtM204I and rtL180M/M204V produced substantially weaker HBV
DNA replicative intermediate signals by Southern blot analysis and less total intracellular HBV DNA by real-time PCR compared
to wild-type virus. The viral polymerase protein of these mutants produced little detectable radiolabeled HBV DNA in an
endogenous polymerase assay. In contrast, the HBV a determinant HBIg/vaccine escape mutants sP120T, sT123N, sG145R, and
sD144E/G145R (that produce rtT128N, Q130P, rtW153Q, and rtG153E respectively) yielded as much virus as wild-type HBV while
the sM133L (rtY141S) mutant was replication impaired. Two of these mutants, rtT128N and rtW153Q, when introduced into a
replication-competent HBV vector containing the rtL180M/M204V polymerase mutation restored the replication phenotype of this
LMV-resistant mutant. These viruses produced levels of intracellular HBV DNA as determined by Southern blot and real-time PCR
that were comparable to those of wild-type HBV, indicating that the changes in the fingers subdomain were able to compensate
for the reduced replication of the LMV-resistant mutations. Since these viruses carry mutations in the a determinant of HBsAg thatINTRODUCTION
Hepatitis B infection is an important cause of cirrhosis
and hepatocellular carcinoma in many areas of the world
including Asia, Africa, the Middle East, and the Pacific
Islands. The treatment options for chronic hepatitis B
infection are currently limited to interferon- and the
nucleoside analogue lamivudine (LMV). Interferon- is
effective in a small subgroup of patients (Hoofnagle and
di Bisceglie, 1997; Niederau et al., 1996; Wong et al.,
1993) and is often limited by the development of adverse
reactions (Hoofnagle and di Bisceglie, 1997). The nucle-
oside analogue LMV is effective both in vitro and in vivo
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88in decreasing hepatitis B virus (HBV) replication. In
the majority of cases treatment with LMV results in a
substantial reduction in the serum HBV DNA levels
and normalization of serum alanine amino-transaminase
(Dienstag et al., 1999b; Liaw et al., 1999; Perillo et al., 1999).
Treatment with LMV stabilizes liver function, produces
hepatitis Be antigen (HBeAg) seroconversion in a sub-
stantial proportion of patients, improves liver histology,
commonly slows disease progression in patients with
cirrhotic liver disease (Dienstag et al., 1999b; Liaw et al.,
1999; Perillo et al., 1999), and in combination with hepa-
titis B immune globulin (HBIg) is highly effective in pre-
venting recurrence of infection following liver transplan-
tation (Markowitz et al., 1998). LMV is also effective in
patients infected with precore mutants of HBV (Lok et al.,
2000; Tassopoulos et al., 1999). However, relapse follow-may potentially decrease the ability of anti-HBs antibody to n
to behave as vaccine escape mutants. © 2002 Elsevier Science (
Parkville, Victoria 3050 Australia. Fax: 61 3 9347 1863. E-mail:
josepht@unimelb.edu.au.
doi:10.1006/viro.2002.1448
0042-6822/02 $35.00e these viruses, these HBV mutants also have the potential
ing the cessation of LMV is common and seroreversion
to HBeAg positivity may also occur (Song et al., 2000).eutraliz
USA)
The long-term treatment of patients with chronic hep-
atitis B with LMV monotherapy is associated with the
selection of drug-resistant HBV mutants and viral break-
through (Allen et al., 1998; Dienstag et al., 1999b; Lau et
al., 2000; Liaw et al., 1999, 2000; Ling and Harrison, 1999;
Ling et al., 1996; Tipples et al., 1996). Up to 65% of
patients treated with LMV continuously for 4 years de-
velop drug-resistant HBV (Allen et al., 1998; Dienstag et
al., 1999b; Hadziyannis et al., 2000; Lau et al., 2000; Liaw
et al., 1999, 2000). LMV-resistant HBV mutants are char-
acterized by the change in the viral polymerase (rt) of
methionine to isoleucine (rtM204I; previously rtM550I) or
valine (rtM204V; previously rtM550V) in the YMDD motif
(Stuyver et al., 2001) of the catalytic center of the enzyme
(Allen et al., 1998; Ling and Harrison, 1999; Ling et al.,
1996; Tipples et al., 1996). The latter mutation is also
accompanied by a compensatory leucine to methionine
change at codon 180 (rtL180M/M204V; previously
rtL526M/M550V) (Allen et al., 1998; Ling and Harrison,
1999; Ling et al., 1996; Tipples et al., 1996). The positions
of these mutations are based on the recently revised
nomenclature for the HBV polymerase (Stuyver et al.,
2001). These mutants are resistant to LMV both in vitro
and in vivo (Ling and Harrison, 1999; Ling et al., 1996;
Ono-Nita et al., 1999a; Tipples et al., 1996). Resistance of
HBV to LMV is explained by steric hindrance between
the oxathiolane ring of LMV-triphosphate and the
-branched chain of isoleucine and valine (Das et al.,
2001) in a manner that is similar to the mechanism
described for human immunodeficiency virus (HIV) (Sara-
fianos et al., 1999).
These mutants have also been reported to be less
“replication fit” compared to wild-type virus in vitro (Me-
legari et al., 1998; Ono-Nita et al., 1999b; Pichoud et al.,
1998). The selection of LMV-resistant mutants is associ-
ated with the reappearance of serum HBV DNA, although
the serum levels generally remain below those before
treatment and the beneficial effects of treatment on dis-
ease progression at least in the short term appear to
remain (Dienstag et al., 1999a,b; Lai et al., 1998; Liaw et
al., 2000). However, the emergence of LMV-resistant mu-
tants has been associated with the development of se-
vere flares of hepatitis (Hadziyannis et al., 2000; Liaw et
al., 1999).
The selection of HBV mutants with amino acid
changes in the a determinant of the HBsAg protein (Fig.
1) has been associated with failure of HBIg and of vac-
cine-induced anti-HBs antibody to neutralize HBV (Wal-
lace and Carman, 1997). As a consequence these vi-
ruses behave as vaccine escape mutants and are capa-
ble of producing infection in vaccinated individuals
(Carman et al., 1990; Karthigesu et al., 1994; Wallace and
Carman, 1997). The potential effect of changes in the
envelope (S) gene on the function of the polymerase
protein is a consequence of the organization of the HBV
genome into frameshifted overlapping reading frames;
the polymerase gene completely overlaps the envelope
gene (Fig. 1). The potential to alter the antigenicity of the
HBsAg protein by changes within the overlapping poly-
merase gene has recently been demonstrated and high-
lights the functional significance of alterations in overlap-
ping polymerase and S reading frames (Torresi et al., 2002).
FIG. 1. Overlap of the HBV polymerase/RT with the HBsAg protein and the a determinant. The HBV polymerase/RT is subdivided into fingers, palm,
and thumb domains as has been described for HIV (Das et al., 2001). The vaccine escape mutations are shown together with the overlapping
LMV-associated changes downstream of the a determinant. The positions of key cysteine residues are shown as shaded circles and the important
disulfide bridges in the HBsAg protein are indicated as broad lines. Two alpha helices, separated by a disulfide bridge in the carboxy-terminal end
of the HBsAg protein are shown as cylindrical structures. Adapted from Carman (1997).
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The HBV polymerase can be divided into a number of
functional domains designated the “fingers,” “palm,” and
“thumb” subdomains by comparison with the reverse tran-
scriptase of HIV (Das et al., 2001; Poch et al., 1989; Sarafi-
anos et al., 1999; Xiong et al., 1999). The YMDD motif is
located in the palm subdomain that is thought to contain
the major catalytic nucleus of the polymerase while the
fingers subdomain contains the region of the enzyme that
overlaps the a determinant of the HBsAg (Fig. 1).
Recently, we reported the occurrence of HBV mutants
in liver transplant recipients with severe recurrent hep-
atitis that demonstrated enhanced replication in vitro in
the presence of LMV (Bock et al., 2002). These mutants
carried combinations of the lamivudine selected
changes rtM204I and rtL180M/M204V in the YMDD motif
and HBIg selected changes in the a determinant of the
HBsAg protein and produced increased in vitro viral DNA
levels in both intracellular replicating HBV core particles
and extracellular virus as measured by Southern blot
hybridization (Bock et al., 2002). In this study we inves-
tigated the role of the fingers subdomain in the activity of
the polymerase protein and the ability of mutations
within this region of the protein selected by changes in
the overlapping S gene to alter the replication phenotype
of HBV with methionine mutated in the YMDD motif.
RESULTS
Restoration of HBV replication phenotype
of LMV-resistant mutants
In order to study the replication phenotype of LMV-
resistant HBV mutant clones, HepG2 cells were trans-
fected with HBV clones harboring changes in the palm
subdomain in and around the YMDD motif of the poly-
merase protein (listed in Table 1). Southern blot analysis
of transfected cell lysates demonstrated that HBV DNA
replication intermediates of the rtM204I and rtL180M/
M204V mutants were reduced in comparison to wild-type
HBV as described by Melegari et al. (1998) (Fig. 2).
In the present study the effects produced by mutations
in the fingers subdomain of the polymerase protein on
the replication of HBV were investigated using Southern
blot analysis of HBV DNA replication intermediates ex-
tracted from transiently transfected HepG2 cells in the
presence of LMV. Two envelope protein mutants, sP120T
and sG145R (corresponding to rtT128N and rtW153Q in
the polymerase protein), were analyzed for their effects
on the HBV polymerase with and without changes in the
YMDD motif in the presence or absence of LMV (Fig. 2).
The appearance of the intracellular HBV DNA replication
intermediates (relaxed circular, linear, and single-
stranded) and levels of intracellular HBV DNA of the
rtT128N and the rtW153Q mutants were comparable to
those of wild-type virus (Fig. 2). The replication of these
three viruses was substantially inhibited by LMV (3.0
M). The LMV-resistant mutants rtM204I and rtL180M/
M204V produced decreased amounts of all HBV DNA
intermediates in comparison to wild-type virus and were
not inhibited by 3.0 M LMV (Delaney et al., 2001) (Fig. 2).
In contrast, the presence of rtT128N and rtW153Q muta-
tions in the fingers subdomain of the polymerase protein
resulting from the changes in the overlapping S gene
(sP120T and sG145R, respectively) partially restored the
replication phenotype of the rtL180M/M204V polymerase
mutant in comparison to wild-type HBV. In addition, these
mutants remained resistant to LMV (3.0 M) (Fig. 2).
Replication of HBV polymerase mutants with changes
in the fingers subdomain
The finding that two specific mutants with changes in
the fingers subdomain were capable of restoring the
TABLE 1
Mutants of HBV and a Comparison of Their Amino Acid Changes within the Wild-type Polymerase and HBsAg Proteins
Mutant virus
(domain of polymerase protein)
Position within the HBsAg protein at which sequence change occurs
120 123 133 144 145 195 196
Wild type P T M D G I W
rtT128N (fingers subdomain) T
rtQ130P (fingers subdomain) N
rtY141S (fingers subdomain) L
rtG153E (fingers subdomain) E R
rtW153Q (fingers subdomain) R
rtL180M
rtM204V (palm subdomain) M
rtM204I (palm subdomain) S
rtL180M/M204V M
Note. The domain of the polymerase protein affected by the respective mutations is indicated in parentheses. Positions within the wild-type HBV
polymerase and HBsAg at which sequence changes occur within the mutant proteins are shown. The amino acid changes are shown in single-letter
code for the individual mutants.
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replication yield of the YVDD LMV-resistant mutant HBV
suggested that this region of the fingers subdomain
could have an important role in the activity of the poly-
merase and HBV replication. To further characterize the
role of this region of the fingers subdomain in activity of
the polymerase protein we next analyzed the replication
phenotype of mutants carrying changes in this subdo-
main alone. The polymerase mutations selected corre-
sponded to S-gene changes that produced HBIg/vaccine
escape HBV mutants and that have been reported pre-
viously (Wallace and Carman, 1997). The changes in the
overlapping fingers subdomain selected as a conse-
quence of the HBsAg protein mutations are shown in
Table 1. The replication phenotype of these mutants was
compared to wild-type HBV by Southern blot hybridiza-
tion.
Southern blot analysis of the HBV replication interme-
diates generated from transient transfection with mu-
tants demonstrated that the single vaccine escape mu-
tants replicated as efficiently as wild-type virus, with the
exception of the rtY141S mutant (Fig. 3A). In addition,
when cells were transfected with mutants carrying either
the rtW153Q or the rtT128N mutations in association with
the LMV-resistant mutation rtL180M/M204V in the ab-
sence of LMV, the replication phenotype of the latter was
restored to near wild-type levels (Fig. 3B). The levels of
single-stranded HBV DNA were greater than those for
the LMV-resistant L180M/M204V mutant (Figs. 2 and 3B).
Restoration of the replication phenotype was not ob-
served when the rtW153Q or the rtT128N mutations were
combined with the rtM204I mutant (Fig. 3B).
We next quantitated intracellular HBV DNA yields con-
ferred by the vaccine escape selected polymerase mu-
tations when combined with the LMV resistance se-
lected mutants using quantitative real-time PCR (Table
2). Both the rtT128N/L180M/M204V and rtW153Q/L180M/
M204V mutants produced levels of intracellular HBV
DNA that were below those of the wild-type virus (53 and
62% of the wild-type HBV DNA level, respectively) but
substantially higher than that of the rtL180M/M204V
alone (2% of the wild-type level) (Table 2). Both the
rtT128N/M204I and rtW153Q/M204I mutants produced
levels of HBV DNA that were only 3.2 and 1.1% of the
wild-type HBV DNA levels (Table 2).
HBV pregenomic RNA encapsidation and intracellular
HBV RNA of fingers subdomain polymerase mutants
We next examined whether changes in the fingers
subdomain of the polymerase protein (rtT128N, rtQ130P,
rtY141S, rtW153Q, and rtG153E) alone could alter the
level of encapsidated HBV RNA of intracellular progeny
viruses. These experiments were performed in order to
determine whether mutations within this specific region
FIG. 2. Southern blot analysis of HBV DNA replication intermediates of mutants carrying changes in both the fingers and the palm subdomains of
the polymerase protein. Transient transfections of HepG2 cells were performed and LMV (3.0 M) was added where indicated. Replication
intermediates are indicated on right as relaxed circular (RC), linear (L), and single-stranded (SS) HBV DNA. The HBV DNA standard comprised a unit
length cloned genome of 3.2 kb. Molecular weight markers (MWM) are shown on the left. Mutants carrying changes in both the fingers and palm
subdomains of the polymerase protein demonstrated partial restoration of the level of HBV DNA (lanes 7 and 13) when compared to mutants carrying
changes in the palm subdomain alone (lanes 15 and 17). The synthesis of HBV DNA of the wild-type virus and of mutants with changes in the fingers
subdomain alone was markedly reduced by LMV.
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of the polymerase could alter the encapsidation of HBV
RNA in isolation of mutations within the YMDD motif and
therefore influence viral replication yield. The levels of
encapsidated HBV RNA in these mutants were all com-
parable to those of wild-type virus. The replication-de-
fective rtY141S mutant also produced an encapsidated
HBV RNA signal that was comparable to that for wild-
type virus (Fig. 4A). These findings confirm that the dif-
ferences in replication phenotype are not the result of
variations in the level of encapsidated HBV RNA. The
synthesis of intracellular HBV RNA transcripts, as deter-
mined by Northern hybridization, of the mutants with
changes in both the fingers and palm subdomains was
also comparable to mutants with changes in the fingers
subdomain alone (Fig. 4B), confirming that these muta-
tions did not influence the production of HBV RNA tran-
scripts. Since the signals of encapsidated HBV RNA
were comparable for mutants with changes in the fingers
subdomain alone (suggesting that the fingers subdomain
mutations did not alter encapsidation of HBV RNA) and
the intensity of signals of total HBV RNA on Northern blot
for the combination mutants were also the same, encap-
sidation assays for the mutants with the combinations of
changes in the fingers subdomain and YMDD motif were
not performed.
Endogenous polymerase assay
To determine whether mutations in the fingers subdo-
main affected polymerase activity we performed endog-
FIG. 3. Southern blot analysis of HBV DNA replication intermediates extracted from cells transfected with mutants carrying changes in the fingers
subdomains alone (A) and in combination with the palm subdomain (B) of the polymerase protein. Replication intermediates are indicated on the right
as relaxed circular (RC), linear (L), and single-stranded (SS) HBV DNA. The HBV DNA standard comprised a unit length cloned genome of 3.2 kb. The
rtW153Q/L180M/M204V and rtT128N/L180M/M204V mutants demonstrated a partial restoration of synthesis of all HBV DNA intermediates. The levels
of all HBV DNA intermediates of the rtY141S mutant were reduced relative to wild-type virus. (C and D) Densitometry analysis comparing SS HBV DNA
of mutant viruses with wild-type HBV.
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enous polymerase assays on virus secreted into culture
supernatants (Fig. 5A). The endogenous polymerase ac-
tivity of mutants with changes in the fingers subdomain
was comparable to that for wild-type HBV with the ex-
ception of the Y141S mutant that demonstrated a re-
duced signal in the polymerase assay (Fig. 5A). In addi-
tion, this mutant produced a stronger linear to relaxed
circular HBV DNA signal than wild-type virus (Fig. 5A),
suggesting that this polymerase may not be able to
process the DNA template as efficiently as wild-type
HBV. Mutants with changes in the YMDD motif of the
palm subdomain alone demonstrated substantially re-
duced polymerase activity (Fig. 5B). Of the mutants with
combined fingers subdomain/vaccine escape and LMV-
resistant mutations the rtT128N/L180M/M204V polymer-
ase mutant demonstrated a partial restoration of activity
while this was not the case for the rtW153Q/L180M/
M204V, rtT128N/M204I, and rtW153Q/M204I polymerase
mutants (Fig. 5C).
DISCUSSION
Significance of polymerase and S gene overlap
The polymerase gene completely overlaps the enve-
lope gene and as a consequence mutations selected in
the envelope gene may produce important mutations in
the polymerase protein. The vaccine and HBIg selected
changes in the region of the envelope gene coding for
the a determinant of the HBsAg protein produce changes
in the overlapping fingers subdomain of the polymerase
protein that could alter the structure and functional ac-
tivity of the enzyme (Fig. 1). We have recently shown the
TABLE 2
Quantitation of Intracellular HBV DNA by Real-Time PCR
Mutant virus
Intracellular viral titer
(copies  106/ml)
by real-time PCR
Level of intracellular
mutant HBV DNA
expressed as %
of wild type
Wild type 167 100
rtM204I 4.6 2.7
rtT128N/M204I 5.3 3.2
rtW153Q/M204I 1.7 1.1
rtL180M/M204V 6 2.0
rtT128N/L180M/M204V 88 53
rtW153Q/L180M/M204V 103 62
Note. HepG2 cells were transfected with HBV wild type and mutant
clones and HBV DNA was extracted and quantitated by real-time PCR.
Mutants carrying changes in the fingers subdomain together with
mutations in the YMDD motif of the palm subdomain are compared to
wild-type HBV.
FIG. 4. (A) HBV RNA encapsidation assay. HBV RNA in progeny wild-type and mutant viruses was extracted and analyzed by Northern blot
hybridization. The encapsidated HBV RNA signal produced by the fingers subdomain mutants was comparable to that of wild-type virus with the
exception of rtY141S. This mutant produced a stronger encapsidated RNA signal than wild-type HBV. (B) Northern hybridization of total intracellular
HBV RNA extracted from Huh 7 cells transfected with HBV mutants carrying changes in both the fingers and palm subdomains of the polymerase
protein. Wild-type, rtQ131P, and rtY141S are not included here as this comparison was restricted to the mutants rtW153Q and rtT128N together with
the accompanying LMV-resistant changes in the YMDD motif. The molecular weights of predicted transcripts are indicated on the right. The
production of HBV transcripts was comparable in cells transfected with mutants carrying changes in the fingers subdomain alone and those with
changes in both the fingers and palm subdomains.
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importance of the overlap between the polymerase and S
genes in a study demonstrating that the LMV selected
polymerase mutations M204I and L180M/M204I produce
changes within the overlapping S gene that result in
HBsAg proteins with reduced antigenicity (Torresi et al.,
2002).
Enhanced replication phenotype of combination HBV
mutants
In this study we found that mutations in the fingers
subdomain of the HBV polymerase protein, selected as a
consequence of vaccine or HBIg selected changes in the
overlapping envelope gene, can partially restore the rep-
lication of some lamivudine-resistant HBV mutants car-
rying changes in the YMDD motif.
The occurrence of unique LMV-resistant HBV mutants
associated with the development of severe hepatitis and
liver failure following recurrence of hepatitis B infection
in liver transplant recipients has been reported (Tillmann
et al., 1999). In vitro studies demonstrated that these
patients were infected with HBV mutants carrying com-
binations of mutations in both the S and polymerase
genes (Bock et al., 2002). The changes in the S gene
overlapped with the fingers subdomain of the polymer-
ase protein. These combination mutants demonstrated
an increased replication phenotype in the presence of
LMV compared to wild-type virus.
The combination HBV mutants examined in our study
produced levels of total intracellular HBV replication in-
termediates that were comparable to wild-type HBV lev-
els while remaining resistant to LMV in vitro. The levels
of single-stranded HBV DNA were greater than those of
the LMV-resistant M204I and L180M/M204V mutants,
reinforcing the compensatory nature of these changes
on the function of the HBV polymerase.
Fingers subdomain mutations
All but one of the mutants carrying amino acid
changes in the fingers subdomain alone demonstrated
levels of replication and polymerase activity that were
comparable to those of the wild-type virus. The levels of
intracellular HBV DNA of the rtT128N/L180M/M204V and
rtT153N/L180M/M204V as determined by real-time PCR
were comparable to wild-type virus levels.
The vaccine escape mutant with the rtY141S change in
the polymerase protein resulted in a virus that behaved
quite differently than wild-type HBV. This virus demon-
strated a replication phenotype that was reduced in
comparison to the wild-type virus as demonstrated by
reduced levels of intracellular HBV DNA replicative in-
termediates on Southern blot. In addition this virus dem-
onstrated a reduced ability to produce relaxed circular
HBV DNA while maintaining the production of double-
stranded linear HBV DNA in the endogenous DNA poly-
merase assay. These findings raise the possibility that
the rtY141S DNA polymerase is unable to adequately
process the HBV DNA template or to correctly perform
the DNA strand transfer required to achieve circulariza-
tion of the HBV genome. These results reinforce the
importance of this region of the HBV DNA polymerase in
the replication of the viral genome.
Restoration of HIV replication fitness
A review of the model structure of the reverse tran-
scriptase of HIV provides a potentially useful insight into
the mechanism by which compensatory mutations may
restore HBV replication levels. An increase in the spec-
ificity of the reverse transcriptase for the binding of the
natural dNTPs or the template-primer accompanies the
development of resistance of HIV to antiviral nucleoside
FIG. 5. Endogenous DNA polymerase assay of secreted wild-type and mutant HBV. Serum-derived HBV is included as a positive control. (A) The
rtW153Q and rtT128N mutants produced radiolabeled HBV DNA signals that were at least comparable to that of wild-type HBV while rtY141S produced
a weaker signal and less relaxed circular DNA than the wild-type enzyme. (B) The palm subdomain polymerase mutants rtM204I and rtL180M/M204V
were unable to effectively incorporate radiolabel into the plus strand of HBV DNA. (C) The addition of the rtT128N change partially restored the
polymerase activity of the rtL180M/M204V mutant but not of rtM204I.
94 TORRESI ET AL.
analogues (Boyer et al., 1994; Tantillo et al., 1994). Vi-
ruses with resistance to nucleoside analogues, non-
nucleoside reverse transcriptase inhibitors, and pro-
tease inhibitors often have reduced replication fitness
(Back et al., 1996; Boyer and Hughes, 1995; Nijhuis et al.,
1999; Sharma and Crumpacker, 1997); however, compen-
satory mutations may also develop within the reverse
transcriptase that restore the level of replication fitness
to wild-type levels while maintaining resistance to the
antiviral agent (Arion et al., 1996; Boyer et al., 1998;
Nijhuis et al., 1999; Schmit et al., 1996). In some in-
stances the infectivity of the mutant viruses produced is
greater than that of wild-type virus (Schmit et al., 1996).
These compensatory mutations may restore replication
fitness by producing an increase in the processivity
(Arion et al., 1996; Boyer et al., 1998, 2000), primer–
template binding (Sarafianos et al., 1999), or fidelity
(Drosopoulos and Prasad, 1996; Oude Essink et al., 1997;
Wainberg et al., 1996) of the reverse transcriptase. From
these studies it may be possible to develop a model that
explains the mechanism by which mutations in the fin-
gers subdomain of the HBV polymerase restore the rep-
lication fitness of LMV-resistant HBV mutants.
Compensatory mutations in the HBV polymerase
Compensatory mutations that restore the replication
phenotype of nucleoside analogue-resistant HBV have
not been widely reported. One study investigating HBV
mutants arising during the course of long-term LMV
therapy described the selection of LMV-resistant mu-
tants distinct from the well-characterized YMDD-motif
mutants (Yeh et al., 2000). These investigators described
a HBV mutant with an rtA181T (previously A527T) change
together with YIDD and YVDD motif mutations. The
rtA181T mutation restored in vitro replication yields of
LMV-resistant HBV mutants and also produced a virus
with an enhanced replication phenotype in the presence
of LMV (Yeh et al., 2000). However, the rtA181T change
produced a stop codon in the overlapping envelope gene
and resulted in impaired secretion of HBsAg and virus.
As a consequence patients carrying this mutant did not
exhibit increased serum HBV DNA levels or progressive
liver disease.
Changes in the fingers subdomain of the polymerase
protein could stabilize important enzymatic functions like
dNTP binding, primer template binding and positioning,
processivity, and fidelity, resulting in the partial restora-
tion of replication of the rtL180M/M204V HBV mutant.
The two envelope gene mutations reported here (sP120T
and sG145R) produce changes of rtT128N and rtW153Q
in the polymerase protein (Fig. 1). Both asparagine and
glutamine have uncharged polar amide side chains that
may alter the dNTP-binding pocket or the primer-tem-
plate positioning.
The pathogenic and clinical significance of combina-
tions of envelope and polymerase gene HBV mutants is
not clear. In addition to the mutations that we have
reported here and elsewhere (Bock et al., 2002), HBV
mutants with other mutations within the HBsAg protein
arising during the course of LMV therapy have been
reported (Lok et al., 2000). However, these investigators
did not examine the replication phenotypes of these HBV
mutants. The potential to select mutants with changes in
the envelope gene/fingers subdomain of the polymerase
together with mutations in the YMDD motif of the poly-
merase protein therefore exists in patients on long-term
LMV therapy (Lok et al., 2000). In some of these patients,
HBV replication may be restored by the selection of
compensatory mutations and result in relapse of hepa-
titis B infection and possibly severe liver disease. Vac-
cine escape mutants capable of causing infection in fully
vaccinated individuals are prevalent in countries with
high endemic rates of hepatitis B infection and universal
HBV vaccination programs (Hsu et al., 1999; Wallace and
Carman, 1997). It has been estimated that vaccine es-
cape mutants will become the dominant HBV quasispe-
cies globally over the next few decades (Wilson et al.,
1998). With this in mind and with the widespread use of
LMV as a treatment for chronic hepatitis B infection, the
selection of combination envelope and polymerase gene
HBV mutants with restoration of HBV replication could
become an important public health problem limiting the
long-term efficacy of nucleoside analogue therapy.
MATERIALS AND METHODS
Plasmid construction
HBV polymerase mutants were made by site-directed
mutagenesis of a replication-competent construct,
pHBV1.5 (subtype adw2), consisting of a 1.5 times full-
length genome of HBV (Bock et al., 1997) using the
“QuickChange” site-directed mutagenesis system (Strat-
agene, La Jolla, CA). Mutations were selected from the
VIDRL database of HBV DNA polymerase gene se-
quences identified from patients on nucleoside analogue
therapy. Mutagenic primers are shown in Table 3. The
panel of vaccine escape mutants with the corresponding
polymerase protein changes is shown in Table 1. The
numbering of the HBV polymerase protein is based on
the new standardized nomenclature as described by
Stuyver et al. (2001). In this system mutations in the HBV
polymerase are preceded by the suffix “rt” while muta-
tions in the HBsAg protein are preceded by the suffix “s”.
All experiments were carried out in duplicate or triplicate.
Cell culture and transfection experiments
HepG2 (human hepatoblastoma) and Huh7 (human
hepatoma) cells were transfected with 5.0 g of the
respective HBV wild-type or mutant clones using Fugene
reagent (Roche Diagnostics, Mannheim, Germany) ac-
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cording to the manufacturer’s instructions. Where indi-
cated 2 h before transfection cells were treated with 3.0
M LMV. A relatively high concentration of LMV was
selected (corresponding to the IC90 of LMV for the inhi-
bition of HBV replication (Delaney et al., 2001)) in order to
achieve almost complete inhibition of LMV-sensitive
HBV. Cells and culture supernatants were harvested at
day 5 for HBV DNA and viral polymerase activity and
harvested after 3 days for HBV RNA analyses.
Southern blot analysis
Transfected cells were lysed with lysis buffer (10 mM
Tris–HCl, pH 7.4, and 1 mM EDTA, pH 8.0, with 100 mM
NaCl and 0.5% NP-40). Cell lysates were clarified by
centrifugation at 13,000 rpm for 3 min at room tempera-
ture followed by digestion at 37°C for 1 h with 50 units of
DNase I (Roche Diagnostics), 0.2 g/ml RNase I, and 1
unit of DpnI (Roche Diagnostics) followed by digestion
with proteinase K (Roche, Diagnostics) in 1% SDS. HBV
DNA was extracted with phenol:chloroform and precipi-
tated with ethanol. After correction for differences in
transfection efficiency using intracellular HBeAg (IMX,
Abbott, Chicago, IL) HBV DNA replication intermediates
were separated by electrophoresis on 1% TAE agarose
gels and transferred to nylon membrane (Amersham Life
Sciences, Braunschweig, Germany). Hybridization was
performed with a 32P-labeled HBV DNA probe as de-
scribed previously (Bock et al., 2000). The replication
phenotype of the HBV mutants was compared to that of
wild-type virus by examining for differences in the HBV
DNA replicative intermediates (double-stranded, linear,
and single-stranded HBV DNA) using a GS-710 Imaging
Densitometer and the Quantity One 4.1.0 software pack-
age (Bio-Rad, Richmond, CA).
HBV DNA real-time PCR analysis
Quantitation of HBV DNA in intracellular lysates of
transfected HepG2 cells was performed using real-time
PCR. This assay provided a measure of replication phe-
notypes by examining for differences in the levels of
intracellular HBV DNA of wild-type and mutant viruses.
Intracellular HBV DNA was extracted as described above
and differences in transfection efficiencies corrected
against intracellular HBeAg levels. Primers and a molec-
ular beacon were designed for conserved nucleic acid
sequences within the precore domain of the HBV ge-
nome to amplify and detect a 216-nucleotide product.
Amplification was performed in a 50-l reaction mixture
containing 1.0 l TaqMan buffer A (Applied Biosystems,
Foster City, CA), 3.0 mM MgCl2, 0.4 pmol of each primer
per microliter, forward primer, PC1 (5GGGAGGAGATT-
AGGTTAA3), and reverse primer, PC2 (5GGCAAAAAC-
GAGAGTAACTC3), 0.4 pmol of the HBV-specific molec-
ular beacon per microliter (5FAM-CGCGTCCTACTGT-
TCAAGCCTCCAAGCTGTGACGCGDABCYL-3; where FAM
represents fluorophore 6-carboxyfluorescein and DABCYL,
4-dimethylaminophenylazobenzoic acid, a quenching
chromophore), and 1.25 U of AmpliTaq Gold DNA poly-
merase (Perkin–Elmer). PCR was performed using the
ABI Prism 7700 spectrofluorometric thermocycler (Ap-
plied Biosystems). The PCR program consisted of an
initial cycle (95°C for 10 min) followed by 45 amplification
cycles (94°C for 15 s, 50°C for 30 s, 72°C for 30 s). The
instrument detected and recorded the fluorescence
spectrum of each reaction tube during the annealing
phase.
An external standard was constructed by ligation of a
1.3-kb sequence (containing wild-type sequence in the
precore region of the HBV genome), into the pBlueBac
vector. Quantification of the DNA concentration of the
plasmid was determined by spectrophotometry. Dupli-
cates of serial 10-fold dilutions of the plasmid ranging
from 108 to 102 copies/ml were included in each run in
order to generate a standard curve. The copy number in
each experimental reaction was determined by interpo-
lation of the derived threshold cycle, calculated as pre-
viously described (Fink et al., 1998; Gibson et al., 1996;
Heid et al., 1996; Lewin et al., 1999).
HBV RNA encapsidation assay
Encapsidated HBV RNA was isolated from transfected
cells 3 days after transfection. Progeny virus was precip-
TABLE 3
Sequences of Oligonucleotides Used for Site-Directed Mutagenesis
Protein mutations Primer sequence
rtT128N 5GGATCAACAACAACCAGTACGGGAACATGCAAAACCTGCACG3
rtQ130P 5CCAGTACGGGACCATGCAAAAACTGCACGACTCCTGCTCAAGG3
rtY141S 5CGACTCCTGCTCAAGGCAACTCTCTGTTTCCCTCATCTTGCTG3
rtW153Q 5GTACAAAACCTACGGACAGAAATTGCACCTG3
rtG153E 5GTACAAAACCTACGGAGAGAAATTGCACCTG3
rtL180M 5CCTCAGTCCGTTTCTCATGGCTCAGTTTACTAG3
rtM204V 5GGCTTTCAGCTATGTGGATGATGTGGTATTGGG3
rtM204I 5GGCTTTCAGCTATATCGATGATGTGGTATTGGGGG3
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itated from cell lysates with polyethylene glycol buffer
(8% PEG 8000, 150 mM NaCl) by incubation on ice for 60
min followed by centrifugation for 20 min at 14,000 rpm
for 20 min. DNase I and RNase I digestion for 1 h at 37°C
eliminated contaminating cytosolic HBV DNA and non-
encapsidated HBV RNA. The HBV core particles were
dissolved in GIT buffer (4 M guanidine thiocyanate, 25
mM sodium citrate, 0.5% sarkosyl, 0.1 M -mercaptoetha-
nol). HBV RNA was extracted with water saturated phe-
nol:chloroform:isoamyl alcohol (25:24:1) and precipitated
with isopropanol. After correction for differences in trans-
fection efficiency using intracellular HBeAg detected in
cell lysates prior to PEG precipitation HBV RNA was
separated on 1% agarose formamide gels, transferred to
nylon membrane (Amersham), and detected with a 32P-
labeled HBV DNA probe.
Northern blot analysis
Northern blot analysis was performed as described
previously (Bock et al., 2000). Briefly, HBV RNA was
extracted from transfected cells using the RNEasy kit
(Qiagen, Hilden, Germany), separated on 1% agarose
formamide gels after differences in transfection effi-
ciency were corrected for using intracellular HBeAg, and
transferred to nylon membrane (Amersham Life Sci-
ences, Braunschweig, Germany). HBV RNA was de-
tected by hybridization with a 32P-labeled HBV DNA
probe and exposure to X-ray film (Fuji).
Quantitation of extracellular HBV titers for
endogenous DNA polymerase assay
Extracellular HBV DNA was quantitated from HBV par-
ticles secreted into cell culture medium. Viral particles
were precipitated from cell culture supernatants using
polyethylene glycol (PEG 8000) as described above. Fol-
lowing DNase I and RNase I digestion, HBV particles
were digested with proteinase K (500 g/ml) in 1% SDS
and HBV DNA was extracted with phenol and chloroform
and precipitated with ethanol. HBV DNA was quantitated
using the Hybrid Capture II assay (Digene Corp., MD)
and viral titers were calculated as copies per milliliter
according to the manufacturer’s instructions.
Endogenous DNA polymerase assay
The HBV DNA endogenous polymerase assay (EPA)
was performed using viral cores isolated from cell cul-
ture supernatants by precipitation with PEG 8000 (8%
PEG 8000, 150 mM NaCl). The amount of virus added for
EPAs was corrected according to viral titers (copies/ml).
The EPA was performed essentially as described previ-
ously (Shaw et al., 1996). Briefly, viral cores were incu-
bated for 10 min at room temperature with 0.5% Triton
X-100 and 25 mM dithiothrietol. EPAs were performed in
the presence of a final concentration of 5 M each of
dATP, dGTP, and dTTP and 5 Ci [32P]dCTP (3000 Ci/
mmol) (Amersham Life Sciences). Reactions were per-
formed in a final volume of 50 l with 0.5% Triton X-100,
100 mM NaCl, 20 mM KCl, 10 mM MgCl2, 2 mM Tris–HCl,
pH 7.4. Polymerase assays were initiated by the addition
of reduced HBV cores to the reaction mixture and incu-
bated at 37°C for 40 min before termination of the reac-
tion by the addition of stop buffer, with reagents to final
concentrations of 0.5% SDS, 150 mM NaCl, 20 mM Tris–
HCl, pH 7.4, 10 mM EDTA, and 500 g/ml proteinase K
(Roche Diagnostics). After overnight incubation at 37°C
radiolabeled products were extracted with phenol:chlo-
roform, precipitated with ethanol, and separated on 1%
TAE agarose gels. Gels were dried at 80°C for 2 h in a
Bio-Rad gel dryer (Bio-Rad) and exposed to film (Fuji).
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